Isis Pharmaceuticals (ISIS) 34.01 $ISIS
Jim Cramer's 'Mad Money' Recap: Playing the Dip for Profit
at The Street - 1 hr 53 mins ago
Unlike traders, investors look at the big picture and focus on longer-term decision making, Cramer says.
How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...
Isis Pharmaceuticals Has Returned 34.1% Since SmarTrend Recommendation (ISIS)
Comtex SmarTrend(R) - Tue Apr 15, 4:54PM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 1 month, Isis Pharmaceuticals has returned 34.08% as of today's recent price of $32.99.
Down 17%: Is Isis Pharmaceuticals Worth Buying Now?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 15, 4:31PM CDT
In just a few months Isis Pharmaceuticals has gone from investment darling to investment dog, dropping nearly 20% since the beginning of this year. But little has changed at Isis, suggesting the recent move lower is tied more to profit-taking...
SmarTrend Watching for Potential Rebound in Shares of Isis Pharmaceuticals After 2.12% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:04PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $32.44 to a high of $35.16. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $33.90 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Research and Markets: Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
Business Wire - Mon Apr 14, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/pcldxf/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering.
Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
M2 - Mon Apr 14, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dhrqp/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering. The Global RNAi Drug Delivery market to grow at a CAGR of 21% to 2018. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. Further, the report states that one of the major challenges in this market is the targeted delivery of RNA therapeutic molecules. During in vivo drug testing procedures, many companies engaged in developing RNA therapeutics found it difficult to deliver the RNA molecules to specific tissues to bring about a therapeutic effect. Key vendors dominating this space are: - Alnylam Pharmaceuticals Inc. - Isis Pharmaceuticals, Inc - Merck & Co. Inc. - Tekmira Pharmaceuticals Corp.. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6d..._rnai_drug
Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Isis Pharmaceuticals Shares Down 24.7% Since SmarTrend's Sell Call (ISIS)
Comtex SmarTrend(R) - Tue Apr 08, 11:07AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 4 weeks, Isis Pharmaceuticals has returned 24.75% as of today's recent price of $37.66.
The Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 9:18AM CDT
Last week was another great one for clinical trial results, although you wouldn't know it looking at biotech and pharmaceutical stock prices. Amgen released robust data from an enormous late-stage program. Isis Pharmaceuticals furthered the...
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
After Yesterday's Decline of 6.41%, Isis Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 03, 5:08PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $38.85 to a high of $42.53. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $39.85 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Isis Pharmaceuticals Shares Down 11.0% Since SmarTrend's Sell Call (ISIS)
Comtex SmarTrend(R) - Tue Apr 01, 10:00AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 3 weeks, Isis Pharmaceuticals has returned 11.00% as of today's recent price of $44.54.
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Isis Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 8 , 2014 at 12:50 p.m. ET in New York, NY.
Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN)
at The Street - Mon Mar 31, 11:03AM CDT
TheStreet's Jim Cramer notes that the "new pharma" stocks, such as Celgene (CELG) and Gilead (GILD), have pulled back significantly recently. Cramer notes that Celgene could earn $16 as early as 2017. He recommends the stock because it is selling for...
Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
PR Newswire - Mon Mar 31, 8:30AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx achieved average reductions of up to 71 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides, and average increases of up to 52 percent in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol. While the starting average triglyceride level in the 300 mg group was 384 mg/dL, 70% of these patients reduced their triglyceride level to below the normal level of 150 mg/dL. In addition, lipoprotein particle analysis showed significant dose-dependent reductions in the number of very low-density lipoprotein (VLDL) particles and significant increases in the number of HDL particles. These new data for ISIS-APOCIIIRx were presented today by Dr. Vickie Alexander at the American College of Cardiology meeting in Washington DC.
Isis Pharmaceuticals Falls 5.81% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 28, 4:58PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $39.53 to a high of $42.55. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $39.53 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Jim Cramer's 'Mad Money' Recap: Playing the Dip for Profit
at The Street - 1 hr 53 mins ago
Unlike traders, investors look at the big picture and focus on longer-term decision making, Cramer says.
How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...
Isis Pharmaceuticals Has Returned 34.1% Since SmarTrend Recommendation (ISIS)
Comtex SmarTrend(R) - Tue Apr 15, 4:54PM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 1 month, Isis Pharmaceuticals has returned 34.08% as of today's recent price of $32.99.
Down 17%: Is Isis Pharmaceuticals Worth Buying Now?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 15, 4:31PM CDT
In just a few months Isis Pharmaceuticals has gone from investment darling to investment dog, dropping nearly 20% since the beginning of this year. But little has changed at Isis, suggesting the recent move lower is tied more to profit-taking...
SmarTrend Watching for Potential Rebound in Shares of Isis Pharmaceuticals After 2.12% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:04PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $32.44 to a high of $35.16. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $33.90 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Research and Markets: Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
Business Wire - Mon Apr 14, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/pcldxf/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering.
Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
M2 - Mon Apr 14, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dhrqp/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering. The Global RNAi Drug Delivery market to grow at a CAGR of 21% to 2018. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. Further, the report states that one of the major challenges in this market is the targeted delivery of RNA therapeutic molecules. During in vivo drug testing procedures, many companies engaged in developing RNA therapeutics found it difficult to deliver the RNA molecules to specific tissues to bring about a therapeutic effect. Key vendors dominating this space are: - Alnylam Pharmaceuticals Inc. - Isis Pharmaceuticals, Inc - Merck & Co. Inc. - Tekmira Pharmaceuticals Corp.. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6d..._rnai_drug
Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Isis Pharmaceuticals Shares Down 24.7% Since SmarTrend's Sell Call (ISIS)
Comtex SmarTrend(R) - Tue Apr 08, 11:07AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 4 weeks, Isis Pharmaceuticals has returned 24.75% as of today's recent price of $37.66.
The Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 9:18AM CDT
Last week was another great one for clinical trial results, although you wouldn't know it looking at biotech and pharmaceutical stock prices. Amgen released robust data from an enormous late-stage program. Isis Pharmaceuticals furthered the...
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
After Yesterday's Decline of 6.41%, Isis Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 03, 5:08PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $38.85 to a high of $42.53. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $39.85 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Isis Pharmaceuticals Shares Down 11.0% Since SmarTrend's Sell Call (ISIS)
Comtex SmarTrend(R) - Tue Apr 01, 10:00AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 3 weeks, Isis Pharmaceuticals has returned 11.00% as of today's recent price of $44.54.
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Isis Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 8 , 2014 at 12:50 p.m. ET in New York, NY.
Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN)
at The Street - Mon Mar 31, 11:03AM CDT
TheStreet's Jim Cramer notes that the "new pharma" stocks, such as Celgene (CELG) and Gilead (GILD), have pulled back significantly recently. Cramer notes that Celgene could earn $16 as early as 2017. He recommends the stock because it is selling for...
Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
PR Newswire - Mon Mar 31, 8:30AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx achieved average reductions of up to 71 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides, and average increases of up to 52 percent in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol. While the starting average triglyceride level in the 300 mg group was 384 mg/dL, 70% of these patients reduced their triglyceride level to below the normal level of 150 mg/dL. In addition, lipoprotein particle analysis showed significant dose-dependent reductions in the number of very low-density lipoprotein (VLDL) particles and significant increases in the number of HDL particles. These new data for ISIS-APOCIIIRx were presented today by Dr. Vickie Alexander at the American College of Cardiology meeting in Washington DC.
Isis Pharmaceuticals Falls 5.81% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 28, 4:58PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $39.53 to a high of $42.55. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $39.53 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
